Dr. Zhuowei Liu 刘卓炜
Oncology
Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public sources. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions
- Deputy Director and Vice President, Sun Yat-sen University Cancer Center
Checked against a public report (2025-10). Positions change; the hospital's website is the final word.
Clinical focus: Surgical treatment of urinary tract tumors, including radical cystectomy with urinary diversion, bladder-preserving comprehensive therapy, and surgery for renal pelvis and ureteral cancer. Uses robotic laparoscopic surgery and multidisciplinary care for urologic tumors.
Conditions and procedures: Bladder cancer, Renal pelvis cancer, Ureteral cancer, Urinary tract tumors
Compiled from public information; not confirmed with the hospital or the doctor.
Name order: in Chinese the family name comes first (Liu Zhuowei). Papers usually list the name as Zhuowei Liu.
Selected publications
26 first- or senior-author papers on PubMed where the author's own affiliation is this hospital (25 since 2016). Most recent:
- Cancer Genet, 2026 (senior author): Urinary cell TWIST1 methylation as a non-invasive dual biomarker: A Multicenter study for early detection and recurrence monitoring in bladder cancer. PubMed 42879988
- Cancer Cell, 2026 (senior author): Lipid oxidation reprogramming in cancer-associated fibroblasts enhances CD8+ T cell cytotoxicity and therapeutic response. PubMed 41687608
- Asian J Urol, 2026 (senior author): Robot-assisted post-chemotherapy retroperitoneal lymph node dissection for metastatic non-seminomatous germ cell tumors using two distinct surgical approaches: A tertiary care experience. PubMed 41815375
- Dev Cell, 2025 (senior author): Targeting VSIG4+ tissue-resident macrophages enhances T cell cytotoxicity and immunotherapy efficacy in cancer. PubMed 40339578
- Adv Sci (Weinh), 2025 (senior author): Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer. PubMed 39656941
- Cell Rep Med, 2024 (senior author): A predictive system comprising serum microRNAs and radiomics for residual retroperitoneal masses in metastatic nonseminomatous germ cell tumors. PubMed 39672156
- Nat Chem Biol, 2024 (senior author): Tumor-repopulating cells evade ferroptosis via PCK2-dependent phospholipid remodeling. PubMed 38720107
- Eur Urol Focus, 2024 (senior author): Overview of Novel Biomarkers for Management of Postchemotherapy Residual Masses in Testicular Cancer. PubMed 38724341
Each paper was checked automatically: the author listed with this name must give this hospital as their affiliation. See the full PubMed search.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and recommend a treatment plan.
Get a specialist opinion